Today's Information

Provided by: PhytoHealth Corporation
SEQ_NO 1 Date of announcement 2022/07/05 Time of announcement 13:42:42
Subject 
 Phytohealth Corporation is invited to Online
Investor Conference held by KGI Securities
Date of events 2022/07/19 To which item it meets paragraph 12
Statement 
1.Date of institutional investor conference:2022/07/19
2.Time of institutional investor conference:14:00
3.Location of institutional investor conference:
Online Investor Conference held by KGI Securities
4.Outline of institutional investor conference:
PhytoHealth is the first listed new drug development Company
on Taiwan Stock Exchange.
The Company's PG2 Lyophilized Injection(懷特血寶凍晶注射劑) is the first
new prescription drugapproved by TFDA and currently the only drug approved
for treatmentof Cancer-Related Fatigue (CRF)，On 2021/3/1, PG2 Lyophilized
Injection obtained the payment of NHI premium formally.
In addition, PhytoHealth's Oraphine also obtained the medicine certificate
 of TFDA.
It is the world's first new oral nalbuphine drug that relieves moderate
to severe pain and has low addiction. It is currently negotiating with
 a number of pharmaceutical companies for licensing.
2 of 9 New Drugs approved by TFDA developed by PhytoHealth until now.
The management team will update the R&D and business development
status during the upcoming investor conference.
5.Any other matters that need to be specified:
Please find the completed financial information on the investor conference
item of the MOPS.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

PhytoHealth Corporation published this content on 05 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 July 2022 06:02:07 UTC.